PD
AKRO

Point72 (DIFC)’s Akero Therapeutics AKRO Stock Holding History

Point72 (DIFC)’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$175K Buy
+3,693
New +$179K 0.01% 470
2025
Q1 		– Sell
-2,950
Closed -$82.1K – 1631
2024
Q4 		$82.1K Buy
2,950
+2,142
+265% +$64.9K ﹤0.01% 1039
2024
Q3 		$23.2K Buy
+808
New +$21.1K ﹤0.01% 1192

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 (DIFC)'s AKRO Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Akero Therapeutics (AKRO) in Q3 2025: 3,693 shares worth $175K. The stake represents 0.01% of the portfolio and ranks #470 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in AKRO as recently as Q4 2024.

Point72 (DIFC) first reported a position in AKRO in Q3 2024 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Point72 (DIFC) held 3,693 shares of Akero Therapeutics worth $175K as of Q3 2025.
  • Akero Therapeutics was a new Point72 (DIFC) position in Q3 2025.
  • Akero Therapeutics made up 0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #470 holding.
  • Point72 (DIFC) first reported a position in Akero Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.